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COST-EFFECTIVENESS OF PARICALCITOL IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM: THE EXPERIENCE IN ITALY
Chiroli S 1 , Lucioni C 2 , Brancaccio D 3 1 Abbott SpA, Campoverde, LT, Italy; 2 Wolters Kluver Health Adis International Ltd, Milano, Italy; 3 Ospedale San Paolo, Milano, Italy OBJECTIVES: To evaluate short-term (12 months) costeffectiveness (CE) of intravenous (iv) vitamin D preparations (paricalcitol and calcitriol) to control hyperparathyroidism in hemodialysis patients. METHODS: A decision analytic model was constructed and analysed from the hospital and the Italian National Health System (INHS) perspectives. Following the indications of the Italian Nephrology Society on the use of iv Vitamin D analogues, patients were simulated to start a 12-month iv Vitamin D treatment when parathormone (PTH) plasmatic level was >700 pg/ml. Starting doses were 27 mg/week for paricalcitol and 9 mg/week for calcitriol; subsequent maintenance dose was adjusted assuming decreasing PTH levels over time. RESULTS: Per patient one-year drug acquisition costs were €3364.74 for paricalcitol and 1883.25 for calcitriol. Calcitriol patients had an average of 0,846 hospitalizations/year more than paricalcitol at an incremental cost, in the INHS perspective (DRG tariffs), of €2868.69. Calcitriol patients had an average of 9.17 hospitalization/days more than paricalcitol at an incremental cost, in the hospital perspective (LOS), of €2249.58. Paricalcitol strategy resulted dominant in both perspectives. Robustness of these findings was demonstrated in multiple sensitivity analyses. CONCLUSIONS: In Italy, paricalcitol greater acquisition costs are offset by reduction in hospitalizations and LOS both from an NHS perspective and from the hospital perspective.
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COST-EFFECTIVENESS OF MIMPARA AMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL
Roze S 1 , Palmer AJ 1 , Standaert B 2 ,Van Kriekinge G 2 1 CORE Center for Outcomes Research, Binningen, Switzerland; 2 Amgen n.v, Brussels, Belgium OBJECTIVES: To demonstrate cost-effectiveness (ICER) of Mimpara (MIM), a drug against secondary hyperparathyroidism (sHPT) in dialysis, compared to standard treatment of care (SOC). METHODS: A Markov model operates in 1 / 2 year cycles and runs over 16 years until the starting cohort reaches 70 years. Mortality risk per cycle was calculated from a 2-year cohort dialysis database (n = 13,000) 1 . The model uses specific distributions for parathyroid hormone (PTH), Calcium (Ca) x Phosphor (P), age, vintage and MIM dosages (30-120 mg/day) from phase III trials. Patients withdrawing from MIM were treated with SOC. Average drug costs were €3109/year first cycle and €2617/year subsequent cycles as only drug responders (85%) remained on study drug. Other treatment costs were taken from a retrospective cost study in Belgium 2 using average daily cost of €214 per dialysis patient plus €50/day for sHPT-sufferer. Annual 3% discount rate was applied to cost and outcome data. RESULTS: Running the model in Monte-Carlo simulation (10,000 iterations) over 16 years, delivered a mortality difference of 0.17 years favoring MIM-use for an extra cost of €8027 (+ dialysis cost) resulting in an ICER of €47,218 per Life Year Gained. Excluding dialysis costs the ICER was €36,970. Sensitivity analyses ranging discount rates from 0% to 6% independently for both outcome and cost data showed ICERs of €36,970 and €59,459 for outcome and €64,517 and €35,088 for cost results, respectively. Evaluating the ICERs over time indicates that costsavings may appear early in MIM-treatment (first 2 to 3 years) due to reductions in co-morbidities without observable survival benefit. CONCLUSION: Including dialysis costs in the ICERequation maintained a reasonable CE-result (<€50,000/LYG) favoring the use of Mimpara for sHPT.
